---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031516"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:09:45.058132+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix reports Q3 2022 revenue $1.9M, net loss $5.05M; PUR1900 Phase 2 on track for Q1 2023

## Summary
- Revenues $1.9M, up from $1.1M YoY; net loss $5.05M ($1.45 per share) vs $8.18M loss in prior year.
- Cash and equivalents $40.7M; expects to fund ops into Q2 2024; raised $1.4M via ATM at ~$5.70/share.
- PUR1900 Phase 2 study for ABPA to start dosing in Q1 2023; 16-week regimen.
- PUR3100 Phase 1 data for acute migraine anticipated early Q1 2023; database lock in November.
- PUR1800 Phase 1b data analysis ongoing for presentation at 2023 medical conference.

## SEC filing metadata
- accession: 0001493152-22-031516
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/0001493152-22-031516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031516
- JSON: https://secwatch.observer/filing/0001493152-22-031516.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031516.txt

## Key facts
- Earnings Releases
  Pulmatrix, Inc. reported the three months ended September 30, 2022 results: revenue $1,872, net income $(5,052), EPS $(1.45) per share.
  - Period: the three months ended September 30, 2022
  - Revenue: $1,872
  - Net income: $(5,052)
  - EPS: $(1.45) per share
  - Result: reported results
  source text: PULMATRIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenues $ 1,872 $ 1,069 $ 4,363 $ 4,713 Operating expenses: Research and development 5,287 4,026 13,773 12,423 General and administrative 1,685 1,656 5,212 4,837 Goodwill impairment - 3,577 - 3,577 Total operating expenses 6,972 9,259 18,985 20,837 Loss from operations (5,100 ) (8,190 ) (14,622 ) (16,124 ) Other income (expense), net: Interest income 102 1 118 6 Other (expense) income, net (54 ) 5 (116 ) (22 ) Total other income (expense), net 48 6 2 (16 ) Net loss $ (5,052 ) $ (8,184 ) $ (14,620 ) $ (16,140 ) Net loss per share attributable to common stockholders – basic and diluted $ (1.45 ) $ (2.91 ) $ (4.32 ) $ (6.08 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/0001493152-22-031516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.